The FDA has released a new checklist meant to clarify the ways a pharmaceutical manufacturer may use scientific and medical literature to promote products. The checklist constitute a revision of 2009 guidelines that were criticized for restricting companies’ ability to “promote the public health.” The new guidelines call for an emphasis on science, not promotion, and also recommends that literature not be funded – either in whole or in part – or distributed by a company.
We could use some more doctors like David Graham, M.D. of the Government Accountability Project:
Correction: Dr. Graham was a client of GAP.